What is Neurocarrus?

Transforming the way we treat pain.

Neurocarrus is a biotech company developing a novel drug technology to safely disrupt pain signals without risk of addiction or other systemic effects.

Learn More

What is Neurocarrus?

Transforming the way we treat pain.

Neurocarrus is a biotechnology company developing a novel drug delivery technology to safely disrupt pain signals without addiction-forming medications or disruption of muscular control.

Learn More

OUR APPROACH

UNMET NEED

OUR TEAM

THE TECHNOLOGY GAP

IN THE UNITED STATES:

Dollars Economic
Cost

reported pain on most
days or every day

experienced pain of any
kind in the past 3 months

Sources: NIH National Health Interview Survey, Institute of Medicine of the National Academies

MILLION ADULTS
EXPERIENCE CATEGORY 4 PAIN

MILLION ADULTS
EXPERIENCE CATEGORY 3 PAIN

ADULTS WITH CATEGORY 3 OR 4 PAIN ARE LIKELY TO:

suffer from more disability

require more frequent and costly health care

have worse health status

Sources: NIH National Health Interview Survey, Institute of Medicine of the National Academies

MARKET SHARE

Market value of
pain therapeutics

Compound annual
growth rate

OUR APPROACH

N-001 is a first-in-class therapeutic designed to treat the physiological symptoms of pain while avoiding systemic absorption and invasive surgical procedures.

Pain is felt when sensory neurons transmit signals to the brain. Current treatments meant to disrupt pain signals from peripheral sensory neurons are not neuron-specific, and consequently suffer from a variety of off-target effects like addiction formation, inhibition of motor neurons, and destruction of the surrounding tissues.

As a superior alternative, Neurocarrus research and development aims to disrupt pain signals from sensory nerve cells via targeted delivery of bacterial proteins. Those proteins modify the neuron's skeleton to block signalling. Unlike other existing FDA approved proteins in the marketplace, N-001 affects just sensory nerves, and leaves motor nerves untouched.

IN THE PIPELINE

Neurocarrus platform technology is under evaluation for:

Delivery of other drugs for nerve regeneration

Nerve fiber imaging as a surgical adjunct

Latest Nature Scientific Reports

First Nature Scientific Reports

OUR APPROACH

N-001 is a first-in-class therapeutic designed to treat the physiological symptoms of pain while avoiding systemic absorption and invasive surgical procedures.

Pain is felt when sensory neurons transmit signals to the brain. Current treatments meant to disrupt pain signals from peripheral sensory neurons are not neuron-specific, and consequently suffer from a variety of off-target effects like addiction formation, inhibition of motor neurons, and destruction of the surrounding tissues.

As a superior alternative, Neurocarrus research and development aims to disrupt pain signals from sensory nerve cells via targeted delivery of bacterial proteins. Those proteins modify the neuron's skeleton to block signalling. Unlike other existing FDA approved proteins in the marketplace, N-001 affects just sensory nerves, and leaves motor nerves untouched.

IN THE PIPELINE

Neurocarrus platform technology is under evaluation for:

Delivery of other drugs for nerve regeneration

Nerve fiber imaging as a surgical adjunct

Nature Scientific Reports research article

First Nature Scientific Reports

ABOUT US

Neurocarrus is developing a breakthrough therapy ( N-001 ) to fulfill the unmet need for a product that can safely and specifically disrupt peripheral sensory neurons. N-001 was engineered for individuals experiencing pain as a result of tissue injury or inflammation as well as patients with acute pain, such as pain following surgery. N-001 is a leading technology in the fight against the opioid crisis, which claims the lives of tens of thousands of Americans each year. A safe, effective treatment for pain, which results in a disease burden of over $635 billion in the US alone, would have a major impact on human health through increased mobility and generally improved life quality. With N-001, we hope to accomplish this without systemic side effects like nausea, dizziness, and addiction.

Headquartered in Monterey/Santa Cruz, CA, Neurocarrus was founded by prominent research scientists in the field of protein engineering, and is led by a strong management team with expertise in business, biotechnology and medicine. Since inception, the company has generated extensive in vitro and in vivo data supporting the efficacy of N-001.

* Institute of Medicine of the National Academies. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. (2012)

CEO and Co-Founder

Paul Blum, Ph.D

ResearchGate

BlumLab

ADVISORS

Jianguo Cheng, MD, Ph.D

Richard Stieg, MD, MHS

Stephen Abramson, Ph.D

Samerender Nagam Hanumantharao, Ph.D

Derek Allen, Ph.D

PARTNERS

NEWS

Neurocarrus received excellent scores and may receive $3M in new nondilutional funding through the United States SBIR program for Neurocarrus Inc. targeting IND-leading studies.

Jan. 2023

N-001 is effective in the first preclinical chronic pain model.

Oct. 2022

Interview with Neurocarrus founder Dr. Paul Blum

June 2, 2022

Heal poster

April 11-12, 2022, Virtual Symposium
Derek Allen, Rylie McDonell, David Clark, Peyman Sahbaie, Samerender Nagam Hanumantharao, Paul Blum. Preclinical Testing of a Novel Recombinant Protein for Acute Nociceptive Pain. Third Annual NIH HEAL Initiative Investigator Meeting.

PCT US 1632573 has issued in Japan 2017-559588 and is pending in Canada, EU, Israel, and South Korea.

June 17, 2021

Neurocarrus second U.S. patent Divisional patent application 16,854,551 granted

May 19, 2021

Neurocarrus seeks Postdoctoral Scientist

October 10th, 2020
A recent pharmacology PhD or equivalent wanted to join Neurocarrus for preclinical development of a novel human pain drug. Prior experience with biologics (proteins) an asset. For more information see the linked posting.

NINDS partners with Neurocarrus to advance N-001

October 9th, 2020
Neurocarrus and the National Institutes of Neurologic Disease and Stroke (NINDS) have agreed to enter N-001 into their internal testing program for new candidate pain therapeutics. This agreement further expands federal nondilutional investment in Neurocarrus.

State of Nebraska invests in N-001 Manufacturing

October 5th, 2020
SBIR/STTR award from Nebraska Department of Economic Development. This additional nondilutional investment supports advances in N-001 manufacturing.

Neurocarrus receives Phase I SBIR Grant, partners with Stanford, VA Palo Alto

September 30th, 2020
Neurocarrus is happy to announce receipt of a Phase I National Institutes of Health (NIH) Small Business Innovation Research (SBIR) award for preclinical development of its candidate human pain drug N-001. This nondilutional investment supports expanded testing of N-001 in collaboration with doctors at Stanford University and VA Palo Alto Medical Center.

Second Nature Scientific Reports article published

July 30th, 2020
Neurocarrus’s second Nature Scientific Reports article was published this month, detailing further exciting advances in our research on N-001.

US Patent and Trademark Office issues key Neurocarrus Patent

April 28, 2020
Neurocarrus has an exclusive license for technology described in Patent No. 10,633,643. Having issued, Neurocarrus can now license this patent as a revenue stream. A divisional patent application will be filed that will further expand the value to Neurocarrus.

CONTACT US

Address

Neurocarrus Inc.

60 Via Buena Vista,
Monterey, CA 93940

Email

[email protected]

What is Neurocarrus?

Transforming the way we treat pain.

Neurocarrus is a biotech company developing a novel drug technology to safely disrupt pain signals without risk of addiction or other systemic effects.

What is Neurocarrus?

Transforming the way we treat pain.

Neurocarrus is a biotechnology company developing a novel drug delivery technology to safely disrupt pain signals without addiction-forming medications or disruption of muscular control.

OUR APPROACH

UNMET NEED

OUR TEAM

THE TECHNOLOGY GAP

IN THE UNITED STATES:

Sources: NIH National Health Interview Survey, Institute of Medicine of the National Academies

suffer from more disability

require more frequent and costly health care

have worse health status

Sources: NIH National Health Interview Survey, Institute of Medicine of the National Academies

MARKET SHARE

OUR APPROACH

N-001 is a first-in-class therapeutic designed to treat the physiological symptoms of pain while avoiding systemic absorption and invasive surgical procedures.

IN THE PIPELINE

Neurocarrus platform technology is under evaluation for: Delivery of other drugs for nerve regeneration Nerve fiber imaging as a surgical adjunct

OUR APPROACH

N-001 is a first-in-class therapeutic designed to treat the physiological symptoms of pain while avoiding systemic absorption and invasive surgical procedures.

IN THE PIPELINE

Neurocarrus platform technology is under evaluation for: Delivery of other drugs for nerve regeneration Nerve fiber imaging as a surgical adjunct

ABOUT US

* Institute of Medicine of the National Academies. Relieving Pain in America: A Blueprint for Transforming Prevention, Care, Education, and Research. (2012)

CEO and Co-Founder

Paul Blum, Ph.D

ADVISORS

Jianguo Cheng, MD, Ph.D

Richard Stieg, MD, MHS

Stephen Abramson, Ph.D

TEAM

Samerender Nagam Hanumantharao, Ph.D

Derek Allen, Ph.D

PARTNERS

NEWS

Neurocarrus received excellent scores and may receive $3M in new nondilutional funding through the United States SBIR program for Neurocarrus Inc. targeting IND-leading studies.

N-001 is effective in the first preclinical chronic pain model.

Interview with Neurocarrus founder Dr. Paul Blum

Heal poster

PCT US 1632573 has issued in Japan 2017-559588 and is pending in Canada, EU, Israel, and South Korea.

Neurocarrus second U.S. patent Divisional patent application 16,854,551 granted

Neurocarrus seeks Postdoctoral Scientist

NINDS partners with Neurocarrus to advance N-001

State of Nebraska invests in N-001 Manufacturing

Neurocarrus receives Phase I SBIR Grant, partners with Stanford, VA Palo Alto

Second Nature Scientific Reports article published

US Patent and Trademark Office issues key Neurocarrus Patent

LINKS

All SEC Filings

CONTACT US

Address

Email

Neurocarrus platform technology is under evaluation for:

Delivery of other drugs for nerve regeneration

Nerve fiber imaging as a surgical adjunct

Neurocarrus platform technology is under evaluation for:

Delivery of other drugs for nerve regeneration

Nerve fiber imaging as a surgical adjunct